Definium Therapeutics, Inc. (DFTX)
Trading disclosure
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for certain activity generated through this link. Prices displayed are informational.
Learn moreKey Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
|
Mr. Robert Barrow
|
CEO & Director | 1.05M | -- | 1989 |
|
Ms. Brandi L. Roberts CPA, M.B.A.
|
Chief Financial Officer | 619.24k | -- | 1974 |
|
Dr. Daniel Rollings Karlin M.A., M.D.
|
Chief Medical Officer | 738.73k | -- | 1980 |
|
Dr. Scott M. Freeman M.D.
|
Co-Founder & Clinical Advisor | 306.2k | -- | 1957 |
|
Mr. Leonard Latchman
|
Co-Founder | -- | -- | -- |
|
Mr. Peter Mack
|
Senior Vice President of Pharmaceutical Development & Operations | -- | -- | -- |
|
Ms. Gitanjali Jain Ogawa
|
VP & Head of Investor Relations | -- | -- | -- |
|
Mr. Mark R. Sullivan J.D.
|
Chief Legal Officer & Corporate Secretary | 638.61k | -- | 1971 |
|
Ms. Beth Calitri
|
Vice President of Corporate Communications | -- | -- | -- |
|
Ms. Stephanie Fagan M.S.
|
Chief Corporate Affairs Officer | -- | -- | -- |
Definium Therapeutics, Inc.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 105
Description
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company's lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York.
Corporate Governance
Upcoming Events
November 9, 2026 at 9:00 PM UTC
Definium Therapeutics, Inc. Earnings Date
